Neuromodulation and Female Sexual Function: Does Treatment for Refractory Voiding Symptoms Have An Added Benefit? - Abstract Show Comments
  
Tuesday, 30 June 2009

Department of Urology, Ministrelli Program for Urology Research and Education (MPURE), William Beaumont Hospital, 3535 W. Thirteen Mile Rd Suite 438, Royal Oak, MI, 48073, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF).

Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months.

Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98).

Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

Written by:
Ingber MS, Ibrahim IA, Killinger KA, Diokno AC, Peters KM.   Are you the author?

Reference:
Int Urogynecol J Pelvic Floor Dysfunct. 2009 May 14. Epub ahead of print.
doi:10.1007/s00192-009-0900-3

PubMed Abstract
PMID:19440647

UroToday.com Overactive Bladder (OAB) Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
Bookmark and Share